DA
SUPN icon

Duality Advisers’s Supernus Pharmaceuticals SUPN Stock Holding History

Duality Advisers’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-8,851
Closed -$300K – 769
2022
Q3 		$300K Buy
+8,851
New +$288K 0.03% 460

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

Duality Advisers's SUPN Position: Q4 2022 in Review

Duality Advisers sold out of Supernus Pharmaceuticals (SUPN) in Q4 2022, closing a stake of 8,851 shares — an estimated $300K sold.

Duality Advisers first reported a position in SUPN in Q3 2022 and held it in 1 quarter. The position peaked at $300K in Q3 2022. 263 funds tracked by Wall St. Rank hold SUPN as of Q4 2022.

  • Duality Advisers reported no remaining Supernus Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Duality Advisers sold 8,851 Supernus Pharmaceuticals shares in Q4 2022, an estimated $300K.
  • Duality Advisers first reported a position in Supernus Pharmaceuticals in Q3 2022 and held it in 1 quarter.
  • Duality Advisers's Supernus Pharmaceuticals position peaked at $300K in Q3 2022.
  • 263 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2022.

Based on Duality Advisers's 13F filing for Q4 2022, filed 7 Feb 2023.